Technology Bundle ID
TAB-757

Oral Treatment of Hemophilia

Linked ID
E-281-2001-0
Lead Inventors
Oral Alpan (NIAID)
Co-Inventors
Polly Matzinger (NIAID)
Tirumalai Kamala (NIAID)
William Velander (Virginia Tech Intellectual Properties, Inc.)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
ICs
NIAID
This invention portrays a simple method for treatment of antigen-deficiency diseases by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. This method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.
Commercial Applications
  • Oral-based treatment for hemophilia A or B
Competitive Advantages
  • Less invasive than current modes of treatment
  • Reduced inflammatory response
  • Immunotolerization against future bleeding episodes

Request More Info

Licensing Contact: